gastric cancer
Conditions
Interventions
experimental group:Conventional treatment+AS21
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Radical surgery for gastric cancer has been performed, and pathological biopsy has confirmed gastric adenocarcinoma; (2) Age>= 18 years old and =1; (4) Receiving preoperative neoadjuvant chemotherapy (SOX regimen) plus immunotherapy (sintilimab or tislelizumab).
Exclusion criteria
Exclusion criteria: (1) Functional constipation or diarrhea, digestive tract diseases such as inflammatory bowel disease, severe abdominal distension with intestinal perforation, immune deficiency, sepsis risk; (2) Patients with systemic diseases, severe heart, lung, kidney, liver dysfunction and metabolic diseases, collagen diseases, endocrine diseases or other malignant solid tumors or hematological tumors (leukemia, lymphoma, etc.), have received radiotherapy and chemotherapy, etc.; (3) Use of antidiarrheal drugs, antispasmodics, probiotics or antibiotic treatment within 1 month before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short-term efficacy;Gastrointestinal symptoms;Dysbiosis of the gut microbiota and changes in metabolites; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of myelosuppression;Routine blood and blood biochemical indicators;Changes in T cell subsets;Quality of life scores;Incidence of tumor recurrence and metastasis;Disease-free survival and overall survival status of the patient; | — |
Countries
China
Contacts
Public ContactGuan Quanlin
The First Hospital of Lanzhou University
Outcome results
None listed